|
US5981562A
(en)
*
|
1996-01-30 |
1999-11-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6066738A
(en)
*
|
1996-01-30 |
2000-05-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6028201A
(en)
*
|
1996-01-30 |
2000-02-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
AU704087B2
(en)
*
|
1996-01-30 |
1999-04-15 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US5968965A
(en)
*
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6300501B1
(en)
|
1996-05-22 |
2001-10-09 |
Warner-Lambert Company |
Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
|
|
US6737410B1
(en)
|
1997-04-11 |
2004-05-18 |
Warner-Lambert Company |
Inhibitors of protein farnesyl transferase
|
|
US6265382B1
(en)
*
|
1997-04-11 |
2001-07-24 |
Warner-Lambert Company |
Dipeptide inhibitors of protein farnesyltransferase
|
|
US20030069231A1
(en)
|
1999-10-12 |
2003-04-10 |
Klaus Rudolf |
Modified aminoacids, pharmaceuticals containing these compounds and method for their production
|
|
WO1999055725A1
(en)
*
|
1998-04-27 |
1999-11-04 |
Warner-Lambert Company |
Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
|
|
WO2000034437A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
US6316436B1
(en)
|
1998-12-08 |
2001-11-13 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
WO2001051494A1
(en)
|
2000-01-12 |
2001-07-19 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
JP2002188646A
(ja)
*
|
2000-12-20 |
2002-07-05 |
Nsk Ltd |
転がり軸受及び軸受装置
|
|
US7595312B2
(en)
|
2002-10-25 |
2009-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
|
|
WO2005049589A2
(en)
*
|
2003-10-14 |
2005-06-02 |
Cadila Healthcare Limited |
Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
|
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
AU2007237904B2
(en)
|
2006-04-19 |
2011-03-03 |
Novartis Ag |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
EP2805945B1
(en)
|
2007-01-10 |
2019-04-03 |
MSD Italia S.r.l. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
EP2132177B1
(en)
|
2007-03-01 |
2013-07-17 |
Novartis AG |
Pim kinase inhibitors and methods of their use
|
|
US8293769B2
(en)
|
2007-05-21 |
2012-10-23 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
|
AU2010307198B9
(en)
|
2009-10-14 |
2014-02-13 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
|
CN103080093A
(zh)
|
2010-03-16 |
2013-05-01 |
达纳－法伯癌症研究所公司 |
吲唑化合物及其应用
|
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
|
EP2601293B1
(en)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
CN103282497B
(zh)
|
2010-08-17 |
2018-07-10 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
|
|
WO2012027236A1
(en)
|
2010-08-23 |
2012-03-01 |
Schering Corporation |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
WO2012143879A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Healthcare Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
JP6290237B2
(ja)
|
2012-11-28 |
2018-03-07 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
癌を処置するための組成物および方法
|
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3057955B1
(en)
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
US10870651B2
(en)
|
2014-12-23 |
2020-12-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
|
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
IL315837A
(en)
|
2017-04-13 |
2024-11-01 |
Sairopa B V |
Anti-SIRP-alpha antibodies
|
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
CA3099763A1
(en)
|
2018-06-25 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Taire family kinase inhibitors and uses thereof
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
KR20210046009A
(ko)
|
2018-08-07 |
2021-04-27 |
머크 샤프 앤드 돔 코포레이션 |
Prmt5 억제제
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
JP7660063B2
(ja)
|
2018-12-28 |
2025-04-10 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
|
|
WO2021126729A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
AU2024228641A1
(en)
|
2023-03-02 |
2025-07-24 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|